Document is current
Any future updates will be listed below
-
Authors
Dehdashti, Farrokh
Wu, Ningying https://orcid.org/0000-0002-0287-7362
Ma, Cynthia X. https://orcid.org/0000-0002-8156-7492
Naughton, Michael J.
Katzenellenbogen, John A. https://orcid.org/0000-0003-0914-0010
Siegel, Barry A. https://orcid.org/0000-0001-6246-5792
- License Information
-
More Information
Article History
Received: 4 May 2020
Accepted: 22 December 2020
First Online: 2 February 2021
Competing interests
: F.D. reports grants from the National Cancer Institute, grants from Siteman Cancer Center/Barnes-Jewish Hospital Foundation during the conduct of the study, and grants from the ECOG-ACRIN Medical Research Foundation and the National Cancer Institute, and grants from NIH/NIBIB outside the submitted work. C.M. reports research funding from Pfizer, consulting fees from Pfizer, AstraZeneca, Eli Lilly, and Novartis. M.N. reports being a speaker for Merck and Esai. J.A.K. was a founder and has an equity interest in Radius Health, Inc., which is developing Elacestrant (RAD 1901), an antiestrogen for breast cancer. B.A.S. reports funding by the ECOG-ACRIN Medical Research Foundation and American College of Radiology for his contribution in administrative roles and also is a consultant for Avid Radiopharmaceutical, Inc., Capella Imaging, LLC., Curium Pharma, General Electric Healthcare, Imaginab, Inc., Progenics Pharmaceuticals, American College of Radiology, American Medical Foundation for Peer Review and Education and Siemens Healthineers.
